Cipher Pharmaceuticals Inc.
CPHRFOTCHealthcare● Active
$12.14
+$0.17(+1.42%)
Market Cap$306913768
P/E Ratio—
52W High$15
52W Low$8.64
Cipher Pharmaceuticals Inc. (CPHRF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CPHRF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.24
Est. $0.14 · +77.8%
Revenue
$0.01B
Est. $0.01B · +2.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
CPHRF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.01B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.21 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $0.14 | $0.24 | +77.8% | $0.01B | $0.01B | +2.6% |
| ▲ Q1 FY2026 | Mar 12, 2026 | $0.15 | $0.51 | +229.0% | $0.01B | $0.01B | -1.4% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $0.15 | $0.21 | +43.5% | $0.01B | $0.02B | -25.1% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $0.16 | $0.22 | +41.0% | $0.01B | $0.02B | -25.7% |
| ▼ Q2 FY2025 | May 8, 2025 | $0.11 | $0.10 | -5.7% | $0.01B | $0.02B | -33.3% |
| ▼ Q1 FY2025 | Mar 18, 2025 | $0.19 | $0.13 | -31.6% | $0.01B | $0.02B | -31.0% |
| ▼ Q4 FY2024 | Nov 7, 2024 | $0.14 | $0.01 | -92.1% | $0.01B | $0.02B | -40.2% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.21
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.24
EPS Est.
$0.14
EPS Surpr.
+77.8%
Revenue
$0.01B
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
$0.51
EPS Est.
$0.15
EPS Surpr.
+229.0%
Revenue
$0.01B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$0.21
EPS Est.
$0.15
EPS Surpr.
+43.5%
Revenue
$0.01B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.22
EPS Est.
$0.16
EPS Surpr.
+41.0%
Revenue
$0.01B
Q2 FY2025
May 8, 2025Miss
EPS Actual
$0.10
EPS Est.
$0.11
EPS Surpr.
-5.7%
Revenue
$0.01B
Q1 FY2025
Mar 18, 2025Miss
EPS Actual
$0.13
EPS Est.
$0.19
EPS Surpr.
-31.6%
Revenue
$0.01B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
$0.01
EPS Est.
$0.14
EPS Surpr.
-92.1%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.24 | $0.25 | $0.26 | 1 |
| Q3 FY2027 | $0.27 | $0.28 | $0.29 | 1 |
| Q2 FY2027 | $0.26 | $0.27 | $0.28 | 1 |
| Q1 FY2027 | $0.22 | $0.23 | $0.23 | 1 |
| Q4 FY2026 | $0.21 | $0.21 | $0.22 | 1 |
| Q3 FY2026 | $0.17 | $0.24 | $0.31 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +77.8% | $13.20 | $13.09 | -0.83% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +229.0% | $10.74 | $10.57 | -1.58% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +43.5% | $10.54 | $10.52 | -0.19% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +41.0% | $9.35 | $9.80 | +4.81% |
| ▼ Q2 FY2025 | May 8, 2025 | -5.7% | $10.44 | $10.54 | +0.96% |
| ▼ Q1 FY2025 | Mar 18, 2025 | -31.6% | $7.90 | $8.37 | +5.95% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -92.1% | $10.82 | $11.08 | +2.40% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +4.5% | $9.40 | $9.88 | +5.11% |
Q2 FY2026-0.83%
Report Date
May 7, 2026
EPS Beat/Miss
+77.8%
Price Before
$13.20
Price After
$13.09
Q1 FY2026-1.58%
Report Date
Mar 12, 2026
EPS Beat/Miss
+229.0%
Price Before
$10.74
Price After
$10.57
Q4 FY2025-0.19%
Report Date
Nov 6, 2025
EPS Beat/Miss
+43.5%
Price Before
$10.54
Price After
$10.52
Q3 FY2025+4.81%
Report Date
Aug 7, 2025
EPS Beat/Miss
+41.0%
Price Before
$9.35
Price After
$9.80
Q2 FY2025+0.96%
Report Date
May 8, 2025
EPS Beat/Miss
-5.7%
Price Before
$10.44
Price After
$10.54
Q1 FY2025+5.95%
Report Date
Mar 18, 2025
EPS Beat/Miss
-31.6%
Price Before
$7.90
Price After
$8.37
Q4 FY2024+2.40%
Report Date
Nov 7, 2024
EPS Beat/Miss
-92.1%
Price Before
$10.82
Price After
$11.08
Q3 FY2024+5.11%
Report Date
Aug 8, 2024
EPS Beat/Miss
+4.5%
Price Before
$9.40
Price After
$9.88
Avg Beat Reaction+1.46%
Avg Miss Reaction+3.10%
Beat Rate5 / 8 quarters
Largest Move+5.95% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CPHRF ends December
Cipher Pharmaceuticals Inc. (CPHRF) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.24 — beating the analyst consensus of $0.14 by +77.8%. CPHRF has beaten EPS estimates for 4 consecutive quarters. The next CPHRF earnings date is expected around September 1, 2026.
Each quarter, investors track CPHRF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CPHRF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CPHRF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CPHRF earnings · 5 questionsCipher Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. CPHRF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CPHRF historically reports after market close (AMC).
CPHRF earnings datewhen is CPHRF earningsCPHRF next earnings datewhen does CPHRF report earningsCPHRF earnings calendar
▸ Source: FMP · Cipher Pharmaceuticals Inc. SEC filings · US GAAP · Cipher Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026